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ABSTRACT
The arc of drug discovery entails a multiparameter op-
timization problem spanning vast length scales. They key
parameters range from solubility (angstroms) to protein-
ligand binding (nanometers) to in vivo toxicity (meters).
Through feature learning—instead of feature engineering—
deep neural networks promise to outperform both tradi-
tional physics-based and knowledge-based machine learn-
ing models for predicting molecular properties pertinent
to drug discovery. To this end, we present the Poten-
tialNet family of graph convolutions. These models are
specifically designed for and achieve state-of-the-art per-
formance for protein-ligand binding affinity. We further
validate these deep neural networks by setting new stan-
dards of performance in several ligand-based tasks. In
parallel, we introduce a new metric, the Regression En-
richment Factor EF
(R)
χ , to measure the early enrichment
of computational models for chemical data. Finally, we
introduce a cross-validation strategy based on structural
homology clustering that can more accurately measure
model generalizability, which crucially distinguishes the
aims of machine learning for drug discovery from standard
machine learning tasks.
I. INTRODUCTION
Most FDA-approved drugs are small organic molecules
that elicit a therapeutic response by binding to a target
biological macromolecule. Once bound, small molecule
ligands either inhibit the binding of other ligands or al-
losterically adjust the target’s conformational ensemble.
Binding is thus crucial to any behavior of a therapeutic
ligand. To maximize a molecule’s therapeutic effect, its
affinity—or binding free energy (∆G)—for the desired tar-
gets must be maximized, while simultaneously minimizing
its affinity for other macromolecules. Historically, scien-
tists have used both cheminformatic and structure-based
approaches to model ligands and their targets, and most
machine learning (ML) approaches use domain expertise-
driven features.
a)Electronic mail: enf@stanford.edu
b)Electronic mail: pande@stanford.edu
More recently, deep neural networks (DNNs) have been
translated to the molecular sciences. Training most con-
ventional DNN architectures requires vast amounts of
data: for example, ImageNet1 currently contains over
14, 000, 000 labeled images. In contrast, the largest pub-
licly available datasets for the properties of drug-like
molecules include PDBBind 20172, with a little over 4, 000
samples of protein-ligand co-crystal structures and asso-
ciated binding affinity values; Tox21 with nearly 10, 000
small molecules and associated toxicity endpoints; QM8
with around 22, 000 small molecules and associated elec-
tronic properties; and ESOL with a little over 1, 000 small
molecules and associated solubility values3. This scarcity
of high-quality scientific data necessitates innovative neu-
ral architectures for molecular machine learning.
Successful DNNs often exploit relevant structure in
data, such as pixel proximity in images. Predicting
protein-ligand binding affinity seems to resemble com-
puter vision problems. Just as neighboring pixels connote
closeness between physical objects, a binding pocket could
be divided into a voxel grid. Here, neighboring voxels
denote neighboring atoms and blocks of empty space. Un-
fortunately, this 3D convolutional approach has several
potential drawbacks. First, inputs and hidden weights
require much more memory in three dimensions. Second,
since the parameters grow exponentially with the number
of dimensions, the model suffers from the “curse of dimen-
sionality”4: while image processing may entail a square
32 filter, the corresponding filter for volumetric molecule
processing has 33 parameters.
In contrast, graph convolutions use fewer parameters
by exploiting molecular structure and symmetry. Con-
sider a carbon bonded to four other atoms. A 3D CNN
would need several different filters to accommodate the
subgroup’s symmetrically equivalent orientations. But a
graph convolution as described in Refs. 5–8 is symmetric
to permutations and relative location of each of the four
neighbors, thereby significantly reducing the number of
model parameters. The use of graph convolutional ap-
proaches to learn molecular properties is reminiscent of
the familiar canon of chemoinformatics algorithms such as
Morgan fingerprints9, SMILES strings10, and the Ullman
algorithm for substructure search11, all of which enrich
chemical descriptions by propagating information about
neighboring atoms.
In this paper, we first review a subset of DNN architec-
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2tures applicable to protein-ligand interaction. Through
the mathematical frameworks above, we contextualize
our presentation of new models that generalize a graph
convolution to include both intramolecular interactions
and noncovalent interactions between different molecules.
First, we describe a staged gated graph neural network,
which distinguishes the derivation of differentiable bonded
atom types from the propagation of information between
different molecules. Second, we describe a more flexible
model based on a new update rule using both the distance
from source to target atom and the target atom’s feature
map. Our direct incorporation of target atom information
into the message function increases signal in some protein-
ligand binding affinity benchmarks. Finally, we address a
potential shortcoming of the standard benchmark in this
space—namely, treating the PDBBind 2007 core set as
a fixed test set—by choosing a cross-validation strategy
that more closely resembles the reality of drug discovery.
Though more challenging, this benchmark may better
reflect a given model’s generalization capacity.
II. NEURAL NETWORK ARCHITECTURES
First, we briefly review a subset of DNN architectures
applicable to protein-ligand interaction in order to moti-
vate the new models we present and test at the end of
the paper.
A. Ligand-based scoring models
1. Fully Connected Neural Networks
The qualitatively simplest models for affinity predic-
tion and related tasks incorporate only features of ligands
and ignore the macromolecular target(s). Such a model
could entail a fully connected neural network (FCNN),
in which each molecule is represented by a flat vector
x containing f0 features. Then, these features are up-
dated through “hidden” layers h by applying nonlinear
activation functions.
The training data for such a network consists of a set
of N molecules, each represented by a vector of length
f0, which have a one-to-one correspondence with a set of
N affinity labels. Domain-expertise driven flat vector fea-
tures might include integer counts of different types of pre-
determined functional groups (e.g., carboxylic acids, aro-
matic rings), polar or nonpolar atoms, and other ligand-
based features. Cheminformatic featurizations include Ex-
tended Circular Fingerprints (ECFP)12 and ROCS13,14.
2. Graph Convolutional Neural Networks
In convolutional neural networks (CNNs), each layer
convolves the previous layer’s feature map with linear
kernels followed by elementwise nonlinearities, producing
FIG. 1. Visual depiction of Gated Graph Neural Network
with atoms as nodes and bonds as edges. The small molecule
propanamide is chosen to illustrate the propagation of infor-
mation among the different update layers of the network.
new features of higher complexity that combine informa-
tion from neighboring pixels15. A graph convolutional
neural network (GCNN) analogously exploits the inherent
structure of data 16. We can represent a given graph
that contains N nodes, fin features per node, and a single
edge type, as consisting of node features x and symmetric
adjacency matrix A, which designates whether a pair of
nodes belong to each other’s neighbor sets N . Consider
the molecule propanamide (Figure 1). For the carbonyl
carbon, the relevant row of the feature matrix x might be
[1, 0, 0] to represent its element, and the corresponding
row of the adjacency matrix A might be [0, 1, 0, 1, 1] to
indicate its bonds to three neighbor atoms.
A graph convolution update, as summarized in 8, entails
applying a function at each node that takes the node and
its neighbors as input and outputs a new set of features
for each node. It can be written as
h
(t+1)
i = U
(t)
h(t)i , ∑
vj∈N(vi)
m(t)(h
(t)
j )
 , (1)
where h
(t)
i represents the node features of node i at hidden
layer t, N(vi) represents the neighbors of node i, and U
(t)
and m(t) are the update and message functions, respec-
tively, at hidden layer t. When there are multiple edge
types, we must define multiple message functions, m(t,e),
which is the message function at layer t for edge type
e ∈ [1, . . . , Net].
Our models are primarily inspired by the Gated Graph
Neural Networks (GGNNs)7. At all layers, the update
function is the familiar gated recurrent unit (GRU). Mes-
sage functions are simple linear operations that are differ-
ent for each edge type but also the same across layers:
h
(t+1)
i = GRU
(
h(t),
Net∑
e
W (e)A(e)h(t)
)
, (2)
3where A(e) is the adjacency matrix, and W (e) the weight
matrix, respectively, for edge type e.
Unlike conventional FCNNs, which learn non-linear
combinations of the input hand-crafted features, the up-
date described in (2) learns nonlinear combinations of
more basic features of a given atom with the features of
its immediate neighbors. Information propagates through
increasingly distant atoms with each graph convolution,
and the GRU enables information to be added selectively.
Ultimately, the GGNN contains and leverages both per-
node features via the feature matrix x and structural
information via the adjacency matrix A. In both classi-
fication and regression settings, GCNN’s terminate in a
“graph gather” step that sums over the rows of the final
embeddings and is invariant to node ordering. The subse-
quent FCNNs produce output of desired size (fout). This
completes the starting point for the graph convolutional
update used in this paper:
h(1) = GRU
(
x,
Net∑
e
W (e)A(e)x
)
...
h(K) = GRU
(
h(K−1),
Net∑
e
W (e)A(e)h(K−1)
)
h(FC0) =
N∑
r=1
[
σ
(
i(h(K), x)
)

(
j(h(K))
)]
r
∈ R(1×fout)
h(FC1) = ReLU
(
W (FC1) · h(FC0)
)
...
h(FCM ) = ReLU
(
W (FCM ) · h(FCM−1)
)
.
(3)
3. Generalization to multitask settings
Predicting affinity for multiple targets by GCNN can
be implemented by training either different models for
each target or by training a single multitask network.
The latter setting has a last weight matrix W (FCM ) ∈
R(T×fFCM−1 ), where T denotes the number of targets in
the dataset. The corresponding multitask loss function
would be the average binary cross-entropy loss across the
targets,
Lossmultitask =
1
T
T∑
j
[
1
nj
nj∑
i
(
yi · log(σ(yˆi))
+ (1− yi) · log(1− σ(yˆi))
)]
.
(4)
B. Structure-based scoring models
Since the advent of biomolecular crystallography by
Perutz et al.17, the drug discovery community has sought
to leverage structural information about the target in ad-
dition to the ligand. Numerous physics-based approaches
have attempted to realize this, including molecular dock-
ing18–21, free energy perturbation22, and QM/MM23,
among others. More recent approaches include RF-
Score24,25, NN-score26, Grid Featurizer3, three dimen-
sional CNN approaches27,28, and Atomic Convolutional
Neural Networks29.
1. PotentialNet Architectures for Molecular Property
Prediction
To motivate architectures for more principled DNN pre-
dictors, we invoke the following notation and framework.
First, we introduce the distance matrix R ∈ R(N×N),
whose entries Rij denote the distance between atomi and
atomj . Thus far, the concept of adjacency, as encoded
in a symmetric matrix A, has been restricted to chem-
ical bonds. However, adjacency can also encompass a
wider range of neighbor types to include non-covalent
interactions (e.g., pi − pi stacking, hydrogen bonds, hy-
drophobic contact). Adjacency need not require domain
expertise: pairwise distances below a threshold value can
also be used. Regardless of particular scheme, we see how
the distance matrix R motivates the construction of an
expanded version of A. In this framework, A becomes a
tensor of shape N ×N ×Net, where Net represents the
number of edge types.
If we order the rows by the membership of atomi to
either the protein or ligand, we can view both A and
R as block matrices, where the diagonal blocks are self-
edges (i.e., bonds and non-covalent interactions) from one
ligand atom to another ligand atom or from one protein
atom to another protein atom, whereas off-diagonal block
matrices encode edges from the protein to the ligand
and from ligand to protein. For illustration purposes, we
choose the special case where there is only one edge type,
Net = 1:
A =

A11 A12 · · · A1N
A21 A22 · · · A2N
...
...
. . .
...
AN1 AN2 · · · ANN
 =
[
AL:L AL:P
AP :L AP :P
]
, (5)
where Aij is 1 for neighbors and 0 otherwise, and A ∈
RN×N . Within this framework, we can mathematically
express a spatial graph convolution—a graph con-
volution based on notions of adjacency predicated on
Euclidean distance—as a generalization of the GGNN
characterized by the update (2).
In addition to edge type generalization, we introduce
nonlinearity in the message portion of the graph convolu-
tional layer:
4h
(K)
i = GRU
h(K−1)i , Net∑
e
∑
j∈N(e)(vi)
NN (e)(h
(K−1)
j )
 ,
(6)
where NN (e) is a neural network for each edge type e
and N (e)(hi) denotes the neighbors of edge type e for
atom/node i.
Finally, we generalize the concept of a layer to the no-
tion of a stage that can span several layers of a given type.
The Staged PotentialNet consists of three main steps: (1)
covalent-only propagation, (2) dual non-covalent and co-
valent propagation, and (3) ligand-based graph gather.
Stage (1), covalent propagation, entails only the first slice
of the adjacency matrix, A(1), which contains a 1 at entry
(i, j) if there is a bond between (atomi, atomj) and a 0
otherwise. Intuitively, stage (1) computes a new set of
vector-valued atom types h
(1)
i for each of the N atoms in
the system based on their local networks of bonded atoms.
Subsequently, stage (2) entails propagation based on both
the full adjacency tensor A which begins with the vector-
valued atom types h
(1)
i computed in (1). While stage (1)
computes new bond-based “atom types” for both amino
acid and ligand atoms, stage (2) passes both bond and
spatial information between the atoms. For instance, if
stage (1) distinguishes an amide carbonyl oxygen from a
ketone carbonyl oxygen, stage (2) might communicate in
the first layer that that carbonyl oxygen is also within 3
Angstroms of a hydrogen bond donor. Finally, in stage
(3) a graph gather is performed solely on the ligand atoms.
The ligand-only graph gather is made computationally
straightforward by the block matrix formulation described
in (5).
PotentialNet, Stage 1:
h
(b1)
i = GRU
xi, Net∑
e
∑
j∈N(e)(vi)
NN (e)(xj)

...
h
(bK)
i = GRU
h(bK−1)i , Net∑
e
∑
j∈N(e)(vi)
NN (e)(h
(bK−1)
j )

h(b) = σ
(
i(b)(h(bK), x)
)

(
j(b)(h(bK))
)
∈ R(N×fb)
(7)
FIG. 2. Visual depiction of multi-staged spatial gated graph
neural network. Stage 1 entails graph convolutions over only
bonds, which derives new node (atom) feature maps roughly
analogous to differentiable atom types in more traditional
forms of molecular modeling. Stage 2 entails both bond-based
and spatial distance based propagation of information. In the
final stage, a graph gather operation is conducted over the
ligand atoms, whose feature maps are derived from bonded
ligand information and spatial proximity to protein atoms.
PotentialNet, Stage 2:
h
(sp1)
i = GRU
h(b)i , Net∑
e
∑
j∈N(e)(vi)
NN (e)(h
(b)
j )

...
h
(spK)
i = GRU
h(spK−1)i , Net∑
e
∑
j∈N(e)(vi)
NN (e)(h
(spK−1)
j )

h(sp) = σ
(
i(sp)(h(spK), h(b))
)

(
j(sp)(h(spK))
)
∈ R(N×fb)
(8)
PotentialNet, Stage 3:
h(FC0) =
NLig∑
j=1
h
(sp)
j
h(FC1) = ReLU
(
W (FC1)h(FC0)
)
...
h(FCK) = W (FCK)h(FCK−1),
(9)
where i(b), j(b), i(sp), j(sp) are bond and spatial neural
networks, and h
(sp)
j denotes the feature map for the j
th
atom at the end of stage 2.
5FIG. 3. PotentialNet Stage 1 exploits only covalent or bonded
interaction edge types encoded in the first slices of the last
dimension of the adjacency tensor A.
FIG. 4. PotentialNet Stage 2 exploits both bonded and non-
bonded interaction edge types spanning the entirety of the
last dimension of the adjacency tensor A.
A theoretically attractive concept in (7) is that atom
types—the 1×fb per-atom feature maps—are derived from
the same initial features for both ligand and protein atoms.
In contrast to molecular dynamics force fields, e.g.30,
which—for historical reasons—have distinct force fields
for ligands and for proteins which then must interoperate
(often poorly) in simulation, our approach derives the
physicochemical properties of biomolecular interactions
from a unified framework.
To further illustrate, PotentialNet Stage 1 and Stage 2
exploit different subsets of the full adjacency tensor A:
III. MEASURING EARLY ENRICHMENT IN
REGRESSION SETTINGS FOR VIRTUAL SCREENING
Traditional metrics of predictor performance suffer from
general problems and drug discovery-specific issues. For
regressors, both R2—the “coefficient of determination”—
and the root-mean-square error (RMSE) are susceptible
to single data point outliers. The RMSE for both clas-
sifiers and regressors account for neither the training
data distribution nor the null model performance. The
area under the receiver operating characteristic curve
(AUC)31 does correct this deficiency in RMSE for clas-
sifiers. However, all aforementioned metrics are global
statistics that equally weight all data points. This prop-
erty is particularly undesirable in drug discovery, which
is most interested in predicting the tails of a distribu-
tion: while model predictions are made against an entire
library containing millions of molecules, one will only pur-
chase or synthesize the top scoring molecules. In response,
the cheminformatics community has adopted the concept
of early enrichment. Methods like BEDROC32 and
LogAUC33 weight the importance of the model’s highest
performers more heavily.
A. Proposed Metric: EF (R)χ
At present, this progress in early enrichment measure-
ment has been limited to classification and has yet to
include regression. Therefore, we propose a new metric
for early enrichment in regression, EF
(R)
χ , analogous to
EFχ. For a given target:
EF (R)χ =
1
χ ·N
χ·N∑
i
yi − y¯
σ(y)
=
1
χ ·N
χ·N∑
i
zi, (10)
in which yi, the experimental (observed) measurement for
sample i, are ranked in descending order according to yˆi,
the model (predicted) measurement for sample i. In other
words, we compute the average z-score for the observed
values of the top χ% scoring samples. We prefer this
approach to computing, for example, 1χ·N
∑χ·N
i (yi − y¯),
which has units that are the same as yi (i.e., log(Ki) val-
ues). Unfortunately, this unnormalized approach depends
on the distribution in the dataset. For instance, in a
distribution of log(Ki) measurements, if the maximum
deviation from the mean is 1.0, the best a model can
possibly perform would be to achieve an EF
(R)
χ of 1.0.
We normalize through division by σ(y), the standard
deviation of the data. This allows comparison of model
performance across datasets with a common unit of mea-
surement but different variances in those measurements.
The upper bound is therefore equal to the right hand
side of (10), where the indexed set of molecules i consti-
tutes the subset of the χ ·N most experimentally active
molecules. This value is dependent on both the distri-
bution of the training data as well as the value χ. The
EF
(R)
χ is an average over χ ·N z-scores, which themselves
are real numbers of standard deviations away from the
6mean experimental activity.∗
IV. RESULTS
A. Cross-validation strategies
It is well known that the performance of DNN algo-
rithms is highly sensitive to chosen hyperparameters. Such
sensitivity underscores the criticality of rigorous cross-
validation35,36. Several recent papers, including works
that claim specifically to improve binding affinity predic-
tion on the PDBBind dataset 37,38, engage in the practice
of searching hyperparmeters directly on the test set. Com-
pounding this problem is a fundamental deficiency of the
main cross-validation procedure used in this subfield that
is discussed below.
While there are newer iterations of the PDBBind
dataset, e.g., Ref. 2, we choose to evaluate performance
on PDBBind 200739,40 to compare performance of our
proposed architectures to previous methods. In previ-
ous works, the PDBBind 2007 dataset was split by (1)
beginning with the “refined” set comprising 1, 300 protein-
ligand co-crystal structures and associated binding free en-
ergy; (2) removing the “core” set comprising 195 samples
to form the test set, with (3) the remaining 1, 095 samples
serving as the training data. We term this train-test split
“PDBBind 2007, Refined Train, Core Test” below, and
compare performance with RF-score25, X-Score41,42, and
the networks (7)-(9) described in this work.
One drawback to train-test split is possible overfitting to
the test set through hyperparameter searching. Another
limitation is that train and test sets will contain similar
examples. Whereas it is typical in other machine learning
disciplines for the train and test set examples to be drawn
from the same statistical distributions, such a setting is
not necessarily desirable in a molecular machine learning
setting43. Drug discovery campaigns typically involve the
synthesis and investigation of novel chemical matter. To
accurately assess the generalizability of a trained model,
the cross-validation strategy should reflect how that model
will be deployed practically. In context of this reasoning,
the “Refined Train, Core Test” strategy is not optimal
for cross-validation. For example, Li and Yang 44 , showed
that systematically removing samples from the PDBBind
2007 refined set with structural or sequence homology to
the core (test) set significantly attenuated the performance
of recent ML-based methods for affinity prediction.
Therefore, we propose and investigate a cross-validation
strategy that splits all data into three distinct folds—train,
validation, and test subsets—with agglomerative hierarchi-
cal clustering based on pairwise structural and sequence
∗ EF (R)χ values may therefore exceed 1.0, since this means that the
χ percentage of top predicted molecules have an average standard
deviation of more than 1.0 above the mean.
homology of the proteins as distance metrics45,46. Fig-
ure 5 contrasts this technique with other common splitting
methods for ligand binding studies. Both sequence and
structural similarity measures are described in Ref. 44.
The agglomerative clustering procedure is described in
detail in Ref. 45 and is a specific case of the method intro-
duced in Ref. 46. Our cross-validation on the PDBBind
2007 refined set with sequence similarity resulted in 978
train samples, 221 valid samples, and 101 test samples
(75%-17%-8%); meanwhile, clustering on structural simi-
larity yielded 925 train samples, 257 valid samples, and
118 test samples (71%-20%-9%). A supplementary file is
provided with the two sets of train, validation, and test
assignments.
FIG. 5. Notional comparison of cross-validation splitting al-
gorithms. The first four vertical panels from the left depict
simple examples of random split, stratified split, time split,
and scaffold split. The rightmost panel depicts a toy example
of the agglomerative split proposed in this work. Both scaffold
split and agglomerative split group similar data points to-
gether in order to promote the generalizability of the network
to new data. Scaffold split uses the algorithm introduced by
Bemis and Murcko 47 to group ligands into common frame-
works. The agglomerative split uses hierarchical agglomerative
clustering to group ligand-protein systems according to pair-
wise sequence or structural similarity of the proteins. This
figure is adapted from Ref. 3 with permission from the Royal
Society of Chemistry.
B. Performance of methods on benchmarks
On the standard PDBBind 2007 “refined train, core
test” benchmark, the PotentialNet Spatial Graph Convo-
lution achieves state-of-the-art performance as reflected
by several metrics. PotentialNet outperforms RF-Score
and X-Score according to Pearson and Spearman correla-
tion coefficients. The Pearson correlation score for (7)-(9)
7TABLE I. Benchmark: PDBBind 2007, Refined Train, Core Test. Error bars are recorded as standard deviation of the test
metric over three random initializations of the best model as determined by average validation set score. MUE is mean unsigned
error. Pearson test scores for TopologyNet are reported from Ref. 37 and RF- and X-Scores are reported from Ref. 44.
Model Test R2 Test EF
(R)
χ Test Pearson Test Spearman Test stdev Test MUE
PotentialNet 0.668 (0.043) 1.643 (0.127) 0.822 (0.021) 0.826 (0.020) 1.388 (0.070) 0.626 (0.037)
PotentialNet, 0.419 (0.234) 1.404 (0.171) 0.650 (0.017) 0.670 (0.014) 1.832 (0.135) 0.839 (0.005)
(ligand-only control)
TopologyNet, N/A N/A 0.826 N/A N/A N/A
No Valid. Set
RF-Score N/A N/A 0.783 0.769 N/A N/A
X-Score N/A N/A 0.643 0.707 N/A N/A
is within error of the reported score for TopologyNet,
the heretofore top performing model on this benchmark.
However, a key caveat must be noted with respect to
this comparison: all cross-validation for this manuscript,
including all of our results reported in Tables I, II, and III,
was performed such that performance on the test set was
recorded for the hyperparameter set that performed most
highly on the validation set. In contrast, the Topology-
Net paper37, models were trained on a combination of
the validation and training sets and evaluated directly
on the test set. Performance for TopologyNet37 therefore
reflects a train-validation type split rather than a train-
validation-test split, which likely inflated the performance
of that method.
Intriguingly, the gap in performance between the Poten-
tialNet Spatial Graph Convolution and the other tested
statistical models changes considerably on the agglom-
erative structure and sequence split benchmarks. On
sequence split, RF-score achieves the best overall perfor-
mance, followed by a statistical tie between the Staged
Spatial Graph Convolution (7)-(9) and X-Score, followed
by the ligand-only graph convolutional control. Mean-
while, on structure split, PotentialNet achieves the highest
overall performance, followed by RF-Score, followed by
a statistical tie of X-Score, and the graph convolutional
ligand-only control.
It is noteworthy that the PotentialNet Spatial Graph
Convolutions ((7)-(9) perform competitively with other
compared methods when the proposed Spatial Graph
Convolutions are predicated on very simple, per-atom
features and pure notions of distance whereas RF-Score,
X-Score, and TopologyNet all directly incorporate domain-
expertise driven information on protein-ligand interac-
tions.
1. Sanity check with a traditional RNN
Given the unreasonable effectiveness of deep learn-
ing methods in mostly unstructured settings, it is im-
portant to justify our incorporation of domain knowl-
edge over a purely deep learning-based approach. To do
this, we trained a bidirectional long short-term memory
(LSTM) network, a commonly-used recurrent neural net-
work (RNN) that handles both past and future context
well. We represented the protein-ligand complexes using
a sequential representation of protein-ligand complexes in
PDBBind: proteins were one-hot encoded by amino acid,
and ligands were similarly encoded on a character-level us-
ing their SMILES string representation. The test Pearson
correlation coefficient corresponding to the best validation
score (using the same metric) was 0.518, far worse than
our results and justifying our model’s incorporation of
domain knowledge.
C. Ligand-based models
While crystallography, NMR, and, most recently, cryo
electron microscopy have opened a new paradigm of
structure-based drug design, many critical tasks of drug
discovery can be predicted from the chemical composition
of a given molecule itself, without explicit knowledge of
the macromolecule(s) to which they bind. Such properties
include electronic spectra (important for parameterizing
small molecule force fields for molecular dynamics simu-
lations, for example), solubility, and animal toxicity.
Quantum mechanical datasets are particularly ripe for
machine learning algorithms since it is straightforward
to generate training data at some known accuracy. The
QM8 dataset48, which contains several electronic prop-
erties for small molecules in the GDB-8 set, lends itself
particularly well for benchmarking PotentialNet (7)-(9)
since each compound’s properties are calculated based on
the three-dimensional coordinates of each element. The
ESOL solubility49 and Tox21 toxicity50 datasets map two-
dimensional molecular representations consisting solely of
atoms and their bonds to their respective single-task and
multi-task outputs, and therefore serve as validation of
our neural network implementations as well as of the value
of incorporating nonlinearity into the message function.
To summarize, our computational experiments indi-
cate that PotentialNet leads to statistically significant
improvements in performance for all three investigated
ligand-based tasks. For the QM8 dataset, we were able
to directly assess the performance benefit that stems
8TABLE II. Benchmark: PDBBind 2007 Refined, Agglomerative Sequence Split. Error bars are recorded as standard deviation of
the test metric over three random initializations of the best model as determined by average validation set score. MUE is mean
unsigned error. X-score does not have error because it is a deterministic linear model.
Model Test R2 Test EF
(R)
χ Test Pearson Test Spearman Test MUE
PotentialNet 0.480 (0.030) 0.867 (0.036) 0.700 (0.003) 0.694 (0.012) 1.680 (0.061)
Ligand-only PotentialNet 0.414 (0.058) 0.883 (0.025) 0.653 (0.031) 0.674 (0.020) 1.712 (0.110)
RF-score 0.527 (0.014) 1.078 (0.143) 0.732 (0.009) 0.723 (0.013) 1.582 (0.034)
X-score 0.470 1.117 0.702 0.764 1.667
TABLE III. Benchmark: PDBBind 2007 Refined, Agglomerative Structure Split. Error bars are recorded as standard deviation
of the test metric over three random initializations of the best model as determined by average validation set score. MUE is
mean unsigned error. X-score does not have error because it is a deterministic linear model.
Model Test R2 Test EF
(R)
χ Test Pearson Test Spearman Test MUE
PotentialNet 0.629 (0.044) 1.576 (0.053) 0.823 (0.023) 0.805 (0.019) 1.553 (0.125)
Ligand-only PotentialNet 0.500 (0.010) 1.498 (0.411) 0.733 (0.007) 0.726 (0.005) 1.700 (0.067)
RF-score 0.594 (0.005) 0.869 (0.090) 0.779 (0.003) 0.757 (0.005) 1.542 (0.046)
X-score 0.517 0.891 0.730 0.751 1.751
from separating spatial graph convolutions into distinct
stages. Recall that Stage I of PotentialNet (7) propagates
information over only bonds and therefore derives differ-
entiable “atom types”, whereas Stage II of PotentialNet
(8) propagates information over both bonds and differ-
ent binned distances. We performed an experiment with
QM8 in which Stage I was essentially skipped, and graph
convolutions propagated both covalent and non-covalent
interactions without a privileged first stage for only cova-
lent interactions. Clearly, separating the two stages led
to a significant boost in performance.
For each ligand model investigation we benchmark
against the error suggested upon introduction of the
dataset, or in order to enable direct comparison with
previously published approaches. For extensive bench-
marking of various models on these and other datasets,
we refer the reader to Ref. 3.
1. Quantum Property Prediction
Table IV reports the performances in mean absolute
error (MAE) over 21786 compounds and 12 tasks in QM8.
We utilize MAE for consistency with the original pro-
posal of the database48. Multiple PotentialNet variants
and two mature deep learning models: deep tensor neural
network51 (DTNN) and message passing neural network8
(MPNN) are evaluated, in which the latter two models
proved to be successful on quantum mechanical tasks
(e.g., atomization energy3). We restricted the training
length to 100 epochs and performed 100 rounds of hyper-
parameter search on PotentialNet models. Staged spatial
PotentialNet model achieved the best performances in the
group, demonstrating strong predictive power on the tasks.
We have also included taskwise results in Appendix B.
2. Toxicity
In the multitask toxicity benchmark, we evaluated the
performances of two graph convolutional type models5,16
and PotentialNet on the Tox21 dataset under same evalu-
ation pattern. With 100 epochs of training, PotentialNet
demonstrated higher ROC-AUC scores on both validation
and test scores, outperforming Weave and GraphConv by
a comfortable margin.
3. Solubility
The same three models are also tested and compared
on a solubility task49, using RMSE to quantify the error
in order to compare to previous work16. PotentialNet
achieved slightly smaller RMSE than Weave and Graph-
Conv (Table VI). Under the limited 100 epochs training,
the final test RMSE is comparable or even superior to
the best scores reported for Weave and GraphConv (0.465
and 0.5216 respectively).
V. DISCUSSION
Spatial Graph Convolutions exhibit state-of-the-art per-
formance in affinity prediction. Whether based on linear
regression, random forests, or other classes of DNNs, all
three of RF-Score, X-Score, and TopologyNet are machine
learning models that explicitly draw upon traditional
physics-based features. Meanwhile, the Spatial Graph
Convolutions presented here use a more principled deep
learning approach. Input features are only basic informa-
tion about atoms, bonds, and distances. This framework
does not use traditional hand-crafted features, such as
hydrophobic effects, pi-stacking, or hydrogen bonding.
9TABLE IV. Quantum Property Prediction with QM8 Dataset. Error bars are recorded as standard deviation of the test metric
over three random initializations of the best model as determined by average validation set score.
Network Valid MAE Test MAE
Spatial PotentialNet, Staged 0.0120 0.0118 (0.0003)
Spatial PotentialNet, SingleUpdate 0.0133 0.0131 (0.0001)
MPNN 0.0142 0.0139 (0.0007)
DTNN 0.0168 0.0163 (0.0010)
TABLE V. Toxicity Prediction with the Tox21 Dataset. Error bars are recorded as standard deviation of the test metric over
three random initializations of the best model as determined by average validation set score.
Network Valid ROC AUC Test ROC AUC
PotentialNet 0.878 0.857 (0.006)
Weave 0.852 0.831 (0.013)
GraphConv 0.858 0.838 (0.001)
XGBoost 0.778 0.808 (0.000)
Instead, higher-level interaction “features” are learned
through intermediate graph convolutional neural network
layers.
The traditional PDBBind 2007 benchmark uses 1, 105
samples from the refined set for training and 195 from the
core set for testing. Here, Spatial Graph Convolutions out-
perform X-Score and RF-Score and perform comparably
with TopologyNet (even though this searched hyperpa-
rameters directly over the test dataset). On our proposed
agglomerative clustering cross-validation benchmark, the
choice of sequence or structure split affects relative perfor-
mance. On sequence split, RF-Score achieved the highest
overall performance, with Staged Spatial Graph Convo-
lutions and X-Score statistically tied for second. But on
structure split, the Staged Spatial Graph Convolutions
performed best, with RF-score in second place.
While the Pearson correlation was employed in the
preceding performance comparison, instead comparing
methods through EF
(R)
χ tells a mildly different story. On
the agglomerative sequence cross-validation split, in which
test proteins are separated from train proteins based on
amino acid sequence deviation, X-Score statistically ties
RF-Score for the best model, while PotentialNet statis-
tically ties the ligand-only PotentialNet control for last
place at over 0.1 average standard deviations worse than
X-Score and RF-Score for the top 5% of predictions. Mean-
while, using the agglomerative structure cross-validation
split, PotentialNet exceeds the performance of X-Score
and RF-Score by over 0.5 average standard deviations,
though is within a statistical tie of the ligand-only Poten-
tialNet control (which has a surprisingly high variance
in its EF
(R)
χ ). Taken together, we aver that it is impor-
tant for the future of ML-driven structure-based drug
discovery to carefully choose both (1) the cross-validation
technique and (2) the metric of performance on held-out
test set in order to most accurately reflect the capacity of
their models to generalize in simulated realistic settings.
In light of the continued importance and success of
ligand-based methods in drug discovery, we benchmarked
PotentialNet on several ligand based tasks: electronic
property (multitask), solubility (single task), and toxicity
prediction (multitask). Statistically significant perfor-
mance increases were observed for all three prediction
tasks. A potentially step change improvement was ob-
served for the QM8 challenge which also reinforced the
value of the concept of stages that privilege bonded from
non-bonded interactions.
Despite the simpler input featurization, Spatial Graph
Convolutions can learn an accurate mapping of protein-
ligand structures to binding free energies using the same
relatively low amount of data as previous expertise-driven
approaches. We thus expect that as larger sets of train-
ing data become available, Spatial Graph Convolutions
can become the gold standard in affinity prediction. Un-
fortunately, such larger, publicly available datasets are
currently nonexistent. We thus call upon academic ex-
perimental scientists and/or their pharmaceutical indus-
try counterparts to release as much high-quality protein-
ligand binding affinity data as possible so the community
can develop and benefit from better affinity prediction
models.
Due to the field’s immense practical applications, our
algorithms must prioritize realizable results over incre-
mental improvements on somewhat arbitrary benchmarks.
We thus also present a new benchmark score and accom-
panying cross-validation procedure. The latter draws on
agglomerative clustering of sequence and structural sim-
ilarity to construct challenging train-test splits. Using
this proposed cross-validation schema, on sequence-based
splitting (Table II) we observe in the Pearson correlation
column that RF-score exceeds X-Score, and X-Score sta-
tistically ties Spatial Graph Convolutions. For structure-
based splitting (Table III) we observe that Spatial Graph
Convolution both RF-Score and X-Score in the Pearson
correlation column. We highlight the Pearson correlation
for consistency with the literature, but present other met-
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TABLE VI. Solubility Prediction with the Delaney ESOL Dataset. Error bars are recorded as standard deviation of the test
metric over three random initializations of the best model as determined by average validation set score.
Network Valid RMSE Test RMSE
PotentialNet 0.517 0.490 (0.014)
Weave 0.549 0.553 (0.035)
GraphConv 0.721 0.648 (0.019)
XGBoost 1.182 0.912 (0.000)
TABLE VII. Hyperparameters for neural networks (7)-(9).
Network Hyperparameter Name Symbol Possible Values
PotentialNet Gather Widths (Bond and Spatial) fbond, fspatial [64, 128]
PotentialNet Number of Bond Convolution Layers bondK [1, 2]
PotentialNet Number of Spatial Convolution Layers spatialK [1, 2, 3]
PotentialNet Gather Width fgather [64, 128]
PotentialNet Number of Graph Convolution Layers K [1, 2, 3]
Both Fully Connected Widths nrows of W
(FCi) [[128, 32, 1], [128, 1], [64, 32, 1], [64, 1]]
Both Learning Rate - [1e-3, 2e-4]
Both Weight Decay - [0., 1e-7, 1e-5, 1e-3]
Both Dropout - [0., 0.25, 0.4, 0.5]
rics in the Tables II and III from which similar conclusions
could be drawn.
This construction (i.e., choice of cross-validation
schema) helps assess models with a practical test set,
such as one containing newly designed compounds on
previously unseen protein targets. Although standard
machine learning practice draws train and test sets from
the same distribution, if machine leaning is to be applied
to real-world drug discovery settings it is imperative that
we accurately measure a given model’s capacity both to
interpolate within familiar regions of chemical space as
well as to generalize to its less charted territories.
METHODS
Models. DNNs were constructed and trained with Py-
Torch52. Custom Python code was used based on RD-
Kit53 and OEChem54 with frequent use of NumPy55 and
SciPy56. Networks were trained on chemical element,
formal charge, hybridization, aromaticity, and the total
numbers of bonds, hydrogens (total and implicit), and rad-
ical electrons. Random forest and linear regression models
(i.e., X-Score) were implemented using scikit-learn57; all
random forests models were trained with 500 trees and 6
features per tree, and the implementation of X-Score is
described in Ref. 44. Hyperparameters for PotentialNet
models trained for binding affinity, electronic properties,
toxicity, and solubility studies are given in Table VII; for
toxicity and solubility models, only bond graph convolu-
tion layers are employed since there are no 3D coordinates
provided for the associated datasets. For these three tasks,
random splitting was used for cross validation. For the
RNN sanity check of the ligand binding task, the best-
performing LSTM sanity check was constructed with 5
layers, a hidden size of 32, 10 classes, and a learning rate
of 3.45e-4.
Cross-validation on PDBBind 2007 core test set bench-
mark. The core set was removed from the refined set
sorted temporally to create the test set. Up to 8 hyper-
parameters were tuned through random search. K-fold
temporal cross validation was conducted within the train
set for each hyperparameter set. For each held-out fold,
validation set performance was recorded at the epoch
with maximal Pearson correlation coefficient between the
labeled and predicted values in the validation set. For
each hyperparameter set, the validation score was the
average Pearson score over the K folds using the best
epoch for each fold. The set with the best validation
score was then used to evaluate test performance. The
training set was split into K temporal folds; for each
fold, test set performance was recorded at the epoch with
highest validation score. All reported metrics are given
as the median with the standard deviation over K folds
in parentheses.
Cross-validation on PDBBind 2007 structure and se-
quence agglomerative clustering split benchmarks. Agglom-
erative clustering was performed with Ward’s method58.
Pairwise distance between PDB proteins was measured as
either 1.0 minus the sequence homology or the TMScore59.
Within the train set, for each hyperparameter set, K ran-
dom splits within the train set were performed. For each
held-out fold, validation set performance was recorded at
the epoch with maximal Pearson correlation coefficient.
The set with the best average Pearson score on the vali-
dation set was used to evaluate test set performance. The
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training set was again randomly split into K folds; for
each fold, test set performance was recorded at the epoch
at which the held out performance was highest according
to Pearson score. Metrics are reported as detailed above.
SAFETY STATEMENT
No unexpected or unusually high safety hazards were
encountered in this study.
SUPPORTING INFORMATION
Sequence- and structure-based agglomerative clustering
cross-validation splittings for the PDBBind 2007 refined
set
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Appendix A: Computational complexity of network
architectures
Here, we consider the complexity of the various neu-
ral architectures discussed in Sec. II, starting with the
simple fully-connected setting. Forward propagation can
be understood as passing an input vector x of length
n through h matrix multiplications, each O(n3), and h
elementwise nonlinear activation layers, each O(n). As-
suming h  n, this yields a total complexity of O(n3).
Since back-propagation involves the same dimensions and
number of layers, just in reverse order, it has the same
complexity as the forward operation.
Complexity analysis for a 2D convolutional neural net-
work, typical in computer vision tasks, is a bit more
involved. An m × n-dimensional filter on an M × N
image yields m × n computations on M × N pixels, in
total O(MNmn). Using the Fast Fourier Transform for
optimized processing, a single convolutional layer will
be O(MN logMN), the same complexity as the entire
network. Notice that these operations’ costs grow expo-
nentially with the dimension of Euclidean data—making
the exploitation of symmetry far more important for 3D
graph data.
The GGNN family of graph convolutional architectures
includes effective optimizations to reduce complexity on
graphs. Let d be the dimension of each node’s internal
hidden representation and n be the number of nodes in
the graph. A single step of message passing for a dense
graph requires O(n2d2) multiplications. Breaking the d
dimensional node embeddings into k different dk dimen-
sional embeddings reduces this runtime to O(n2d2k ). As
most molecules are sparse or relatively small graphs, these
layers are typically O(nd2k ). Although other optimizations
exist, such as utilizing spectral representations of graphs,
the models presented in this work build around this gen-
eral GGNN framework with different nonlinearities and
update rules. None of these are sufficiently computation-
ally expensive enough to alter the total runtime.
Appendix B: Taskwise results for quantum property
prediction
TABLE VIII. QM8 Test Set Performances of All Tasks (Mean
Absolute Error)
Task DTNN MPNN PotentialNet, PotentialNet,
Single Update Staged
E1 - CC2 0.0092 0.0084 0.0070 0.0068
E2 - CC2 0.0092 0.0091 0.0079 0.0074
f1 - CC2 0.0182 0.0151 0.0137 0.0134
f2 - CC2 0.0377 0.0314 0.0296 0.0285
E1 - PBE0 0.0090 0.0083 0.0070 0.0067
E2 - PBE0 0.0086 0.0086 0.0074 0.0070
f1 - PBE0 0.0155 0.0123 0.0112 0.0108
f2 - PBE0 0.0281 0.0236 0.0228 0.0215
E1 - CAM 0.0086 0.0079 0.0066 0.0063
E2 - CAM 0.0082 0.0082 0.0069 0.0064
f1 - CAM 0.0180 0.0134 0.0123 0.0117
f2 - CAM 0.0322 0.0258 0.0245 0.0233
In Table VIII we have recorded the test set perfor-
mances for all twelve tasks in the QM8 dataset using the
MAE for a deep tensor neural network51 (DTNN), a mes-
sage passing neural network8 (MPNN), and the staged
and single update Spatial PotentialNet networks as in
Sec. II B 1.
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